Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 1061-1070

  Castells, Lluís ^a   Esteban, Juan I ^a   Bilbao, Itxarone ^a   Vargas, Victor ^a   Allende, Helena ^a   Ribera, Esteban ^a   Piron, Maria ^a   Sauleda, Silvia ^a   Len, Oscar ^a   Pahissa, Albert ^a   Esteban, Rafael ^a   Guardia, Jaime ^a   Margarit, Carlos ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA2B INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIVIRUS AGENT; BASILIXIMAB; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RITONAVIR; RNA; STAVUDINE; STEROID; TACROLIMUS; TENOFOVIR; VALGANCICLOVIR; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MITOCHONDRIAL TOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DNA, MITOCHONDRIAL; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; LEUKOCYTES, MONONUCLEAR; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 33845653617     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998; 338:853-860.
2. Soriano V, García-Samaniego J, Bravo R, et al. Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus. Med Clin (Bar) 1995; 104:641-644.
3. Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-aquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
4. Salmon-Ceron D, Lewden CH, Morlat PH, et al. Liver disease as a major cause of death among HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
5. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779-789.
6. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11:1425-1430.
7. Torriani FJ, Rodriguez Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
8. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated-interferon-alfa-2b vs interferon-alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292:2839-2848.
9. Ogedegbe AEO, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003; 3:329-337.
10. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
11. Prachalias AA, Pozniak A, Taylor C, et al. Liver transplantation in adults co-infected with HIV. Transplantation 2001; 72:1684-1688.
12. Samuel D, Duclos J, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J Hepatol 2003; 39:3-6.
13. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412-1420.
14. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239-247.
15. Norris S, Taylor Ch, Muisean P, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10:1271-1278.
16. Moreno S, Fortún J, Quereda C, et al. Liver transplantation in HIV-infected patients. Liver Transpl 2005; 11:76-81.
17. Rafecas A, Rufi G, Figueras J, et al. Liver transplantation without steroid induction in HIV-infected patients. Liver Transpl 2004; 10:1320-1323.
18. Duclos-Vallée J, Vittecoq D, Teicher E, et al. Hepatitis C virus recurrence and liver mitochondrial damage alter liver transplantation in HIV-HCV coinfected patients. J Hepatol 2005; 42:341-349.
19. Duclos-Vallée J, Feray C, Roque-Afonso AM, Casting D, Samuel D. Recurrence of hepatitis C virus is more severe in liver transplanted HIV-HCV coinfected patients than in HCV mono-infected patients. Liver Transpl 2005; 11:C-3.
20. Radecke K, Fruhauf NR, Miller M, et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int 2005; 25:101-108.
21. Schvarcz R, Soderdahl G. Successful hepatitis C virus treatment in patients co-infected with HIV after liver transplantation. Transplantation 2005; 79:853.
22. Vogel M, Voigt E, Schäfer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11:1515-1521.
23. Miro JM, Torre-Cisnero J, Moreno A, et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain. Enferm Infecc Microbiol Clin 2005; 23:353-362. [Spanish]
24. CDC - 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (No RR-17)
25. Sauleda S, Esteban JI, Juarez A, et al. Preventing lactic acidosis in HIV HCV coinfected patients during interferon and ribavirin treatment. Development of a real-time PCR for mitochondrial DNA copy number in PBMCs. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. 1-5 November 2002, Boston, MA, USA. Abstract 256.
26. Demetris AJ, Eghtesad B, Marcos A, et al. Recurrent hepatitis C in liver allografts. Prospective assessment of diagnostic accuracy, identification of pitfalls and observations about pathogenesis. Am J Surg Pathol 2004; 28:658-669.
27. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
28. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 2002; 36(5 Suppl 1):S3-20.
29. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23:971-976.
30. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine and efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189.
31. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
32. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25.
33. Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl 2004; 10:699-702.
34. Jain AKB, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8:841-845.
35. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38:34-41.
36. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11:386-395.
37. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (a-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43:53-59.
38. Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995; 27:1222-1223.
39. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieus J, et al. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500-504.
40. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation 2005; 79:261-268.
41. Brown RS, Jr. Hepatitis C and liver transplantation. Nature 2005; 436:973-978.
42. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10:1233-1239.
43. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001;7:790-796.
44. Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11:1207-1213.
45. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924.
46. Kanda T, Yokosuka O, Imazeki F, et al. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 2004; 11:479-487.
47. Nuñez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antiviral Ther 2005; 10:657-662.
48. Jain AKB, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8:1007-1013.
49. Lewis J, Huq A, Najarro P. Inhibition of mitochondrial function by interferon. J Biol Chem 1996; 271:13184-13190.
50. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9:348-353.
51. Kornberg A, Küpper B, Hommann M, et al. Antiviral long-term maintenance therapy with interferon and ribavirin for recurrent hepatitis C after liver transplantation-impact on allograft morphology and long-term survival. Transpl Int 2005; 18(Suppl 1):189.